Cure is a preeminent developer and manufacturer of the most advanced oral thin film (OTF) on the market today with an industry leading full service cGMP manufacturer. Cure offers the most advanced development and manufacturing of nutraceuticals, OTC products, pharmaceuticals, and veterinary medicants in a patented, proprietary, OTF delivery system. Alongside its stand-alone OTF technology, Cure has developed an array of products in cutting-edge delivery platforms such as, sublingual and transdermal applications. Collectively Cure brings over 90 years of experience formulating and manufacturing nutraceuticals, OTC products, pharmaceuticals, and veterinary medications placing quality and service as our top priorities, thus earning us the trust and respect of customers worldwide.

IR Nav

Company Profile

1620 Beacon Place
Oxnard, California 93033

(805) 824-0410

(805) 487-7163



Intraday stock chart for CURR


Robert Davidson


Edward Maliski

PhD, President and Chief Science Officer

Wayne Nasby

Chief Operations Officer

Mark Udell

Chief Financial Officer

Jessica Rousset

Chief Business Officer

Eric E. Allen, PhD

Director of Research and Development

View Management Team

Past Six Months

6 month stock chart for CURR

Investor Relations

Mark Udell
CURE Pharmaceutical

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: (212) 828-8436
Facsimile: (646) 536-3179


805 3rd Ave., #1430
New York, NY 10022
(917) 229-4610

Corporate Counsel

Carmel, Milazzo & DiChiara, LLP
Peter DiChiara, Esq.
261 Madison Avenue, 9th Floor
New York, NY 10016
(212) 658-0458

Subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.